Numinus Wellness Inc. Announces Second Quarter Fiscal 2025 Results
Numinus Wellness (OTCQB:NUMIF), a mental health care company specializing in psychedelic-assisted therapies, reported its Q2 2025 financial results. The company achieved total revenue of C$1.51 million, representing an 83.8% increase from Q2 2024. Despite revenue growth, gross profit margin declined to 33.4% from 55.6% year-over-year.
The company reported a comprehensive loss of C$7.71 million, wider than the previous year's loss of C$5.96 million. Operating expenses increased by 86.31% to C$9.89 million. As of February 28, 2025, Numinus maintained cash and cash equivalents of C$705,631.
Numinus Wellness (OTCQB:NUMIF), azienda nel settore della salute mentale specializzata in terapie assistite da psichedelici, ha reso noti i risultati finanziari del secondo trimestre 2025. La societ脿 ha registrato ricavi totali di C$1,51 milioni, con un incremento dell'83,8% rispetto al secondo trimestre 2024. Nonostante la crescita dei ricavi, il margine di profitto lordo 猫 sceso al 33,4% rispetto al 55,6% dell'anno precedente.
Numinus ha riportato una perdita complessiva di C$7,71 milioni, superiore alla perdita di C$5,96 milioni dell'anno precedente. Le spese operative sono aumentate del 86,31%, raggiungendo C$9,89 milioni. Al 28 febbraio 2025 la societ脿 disponeva di liquidit脿 e mezzi equivalenti per C$705.631.
Numinus Wellness (OTCQB:NUMIF), compa帽铆a de atenci贸n de la salud mental especializada en terapias asistidas por psicod茅licos, present贸 sus resultados financieros del segundo trimestre de 2025. La empresa alcanz贸 ingresos totales de C$1,51 millones, lo que supone un aumento del 83,8% respecto al segundo trimestre de 2024. A pesar del crecimiento de ingresos, el margen bruto se redujo al 33,4% desde el 55,6% interanual.
La compa帽铆a registr贸 una p茅rdida integral de C$7,71 millones, superior a la p茅rdida de C$5,96 millones del a帽o anterior. Los gastos operativos aumentaron un 86,31%, hasta C$9,89 millones. Al 28 de febrero de 2025, Numinus contaba con efectivo y equivalentes de C$705.631.
Numinus Wellness (OTCQB:NUMIF)電� 靷澊韨る嵏毽� 氤挫“ 旃橂毳� 鞝勲鞙茧 頃橂姅 鞝曥嫚瓯搓皶 旒�鞏� 旮办梾鞙茧 2025須岅硠鞐半弰 2攵勱赴 鞁れ爜鞚� 氚滍憸頄堨姷雼堧嫟. 须岇偓电� 齑濎垬鞚� C$1.51氚彪鞚� 雼劚頃橃棳 2024雲� 2攵勱赴 雽�牍� 83.8% 歃濌皜頄堨姷雼堧嫟. 靾橃澋鞚� 歃濌皜頄堨潓鞐愲弰 攵堦惮頃橁碃 毵れ稖齑濎澊鞚惦鞚� 鞝勲厔 霃欔赴鞚� 55.6%鞐愳劀 33.4%搿� 頃橂澖頄堨姷雼堧嫟.
须岇偓电� 韽磩靻愳嫟 C$7.71氚彪鞚� 氤搓碃頄堨溂氅�, 鞚措姅 鞝勲厔鞚� C$5.96氚彪 靻愳嫟氤措嫟 頇曤寑霅� 靾橃箻鞛呺媹雼�. 鞓侅梾牍勳毄鞚� 86.31% 歃濌皜頃� C$9.89氚彪鞚� 旮半頄堨姷雼堧嫟. 2025雲� 2鞗� 28鞚� 旮办 Numinus鞚� 順勱笀 氚� 順勱笀靹� 鞛愳偘鞚� C$705,631鞛呺媹雼�.
Numinus Wellness (OTCQB:NUMIF), soci茅t茅 de soins en sant茅 mentale sp茅cialis茅e dans les th茅rapies assist茅es par psych茅d茅liques, a publi茅 ses r茅sultats financiers pour le deuxi猫me trimestre 2025. L'entreprise a r茅alis茅 un chiffre d'affaires total de C$1,51 million, soit une hausse de 83,8% par rapport au T2 2024. Malgr茅 cette croissance, la marge brute a diminu茅 脿 33,4% contre 55,6% l'ann茅e pr茅c茅dente.
La soci茅t茅 a enregistr茅 une perte globale de C$7,71 millions, plus importante que la perte de C$5,96 millions de l'an pass茅. Les charges d'exploitation ont augment茅 de 86,31% pour atteindre C$9,89 millions. Au 28 f茅vrier 2025, Numinus disposait de liquidit茅s et 茅quivalents de C$705 631.
Numinus Wellness (OTCQB:NUMIF), ein Unternehmen f眉r psychische Gesundheit, das sich auf psychedelisch unterst眉tzte Therapien spezialisiert hat, ver枚ffentlichte seine Finanzergebnisse f眉r das zweite Quartal 2025. Das Unternehmen erzielte Gesamtumsatz von C$1,51 Mio., was einem Anstieg von 83,8% gegen眉ber dem zweiten Quartal 2024 entspricht. Trotz des Umsatzwachstums sank die Bruttogewinnmarge von 55,6% auf 33,4%.
Das Unternehmen meldete einen umfassenden Verlust von C$7,71 Mio., der h枚her ausfiel als der Verlust von C$5,96 Mio. im Vorjahr. Die betrieblichen Aufwendungen stiegen um 86,31% auf C$9,89 Mio. Zum 28. Februar 2025 verf眉gte Numinus 眉ber Zahlungsmittel und Zahlungsmittel盲quivalente in H枚he von C$705.631.
- None.
- Gross profit margin declined significantly from 55.6% to 33.4%
- Operating expenses increased by 86.31% to C$9.89 million
- Net loss widened to C$7.71 million from C$5.96 million year-over-year
- Low cash position of C$705,631 raises potential liquidity concerns
All financial results are reported in Canadian dollars unless otherwise stated.
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended February 28, 2025 ("Q2 2025").
Q2 2025 Performance Metrics
| For the quarter ended: | |||||||||
| Feb 28, 2025 (Q2 2025) | Feb 28, 2024 (Q2 2024) | % change | |||||||
| Total Revenue | $ | 1,512,435 | $ | 822,973 | |||||
| Cost of revenue | 1,007,691 | 365,446 | |||||||
| Gross Profit (Loss) | $ | 504,744 | $ | 457,527 | |||||
| Gross profit margin (loss) | -400 bps | ||||||||
| Operating expenses and other items | 9,886,497 | 5,306,523 | |||||||
| Loss and comprehensive loss | ( | ) | ( | ) | n/a | ||||
Balance Sheet and Liquidity
Numinus ended the quarter with cash and cash equivalents of
Numinus' unaudited condensed consolidated interim financial statements for the three months ended February 28, 2025, and related management's discussion and analysis are available on Numinus' Investor Relations website at and under the Company's profile on SEDAR+ at . These documents were prepared in accordance with IFRS.
About Numinus
Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model — including psychedelic research and clinic care — is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
Learn more at and follow us on , , , and .
SOURCE: Numinus Wellness Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including, without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are "forward-looking statements". Forward-looking statements can be identified by the use of words such as "expects", "does not expect", "is expected", "believes", "intends", "anticipates", "does not anticipate", "believes" or variations of these words, expressions or statements, that certain actions, events or results "may", "could", "would", "might" or "will be" taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, ability of Numinus to maintain or increase earnings; ability of Numinus to achieve or maintain profitability; results of changes to operations from a financial or business perspective; the effect of cost containment measures on Numinus business and financial position; changes to cash burn rate, expenses, corporate programs or priorities, or unanticipated costs affecting cash runway or the pathway to positive cashflow or profitability, interest in, uptake of and the ability to commercialize the Numinus Training; availability of subjects and trainers for experiential opportunities in practitioners training, if approved; dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate the Company's facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal, state and provincial legalization, if any, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company's need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers; and other risk factors set forth in our annual information form dated July 25, 2025 and available on SEDAR+ at . These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company's efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws.
For more information:
Investor Contact
Craig MacPhail
[email protected]
To view the source version of this press release, please visit
FAQ
What was Numinus Wellness (NUMIF) revenue in Q2 2025?
How much did Numinus Wellness (NUMIF) lose in Q2 2025?
What is Numinus Wellness (NUMIF) current cash position?
How did Numinus Wellness (NUMIF) gross margin change in Q2 2025?
What caused the increased losses at Numinus Wellness (NUMIF) in Q2 2025?
